Publication

Structurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease

Lipids 57(4-5):241-255, 2022

Secor JD, Cho BS, Yu LJ, Pan A, Ko VH, Dao DT, Feigh M, Anez-Bustillos L, Fell GL, Fraser DA, Gura KM, Puder M

View publication

Share this page

Resource Library

Related resources

Disease progression and pharmacological intervention in a nutrient-deficient rat model of nonalcoholic steatohepatitis

Disease progression in the non-obese CDAA-HFD mouse model of advanced NASH and fibrosis

Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 2650